Literature DB >> 23649409

Volatile substance misuse: an updated review of toxicity and treatment.

Jonathan B Ford1, Mark E Sutter, Kelly P Owen, Timothy E Albertson.   

Abstract

Educational campaigns and legislative actions may have led to an overall decrease in the prevalence of volatile substance misuse (VSM) in many countries; however, it is still a common practice throughout the world. Studies currently suggest that girls are misusing volatile substances more than before and at a prevalence rate equal to or exceeding that of boys in several countries. Products that may be misused are ubiquitous and relatively easy to acquire. The most commonly misused substances in recent studies are fuels such as butane or petrol and compressed gas dusters and deodorants that may contain fluorocarbons and/or butane. Detection of VSM is challenging, therefore physicians must maintain a high level of suspicion based on history and clinical presentation. Clues to misuse are often subtle and may include the patient's proximity to a volatile substance or paraphernalia when found intoxicated, dermal burns, blisters, pigments, or rashes, and chemical odors. The primary targets of toxicity are the brain and the heart. The leading cause of death from VSM is from ventricular dysrhythmias. Treatment of toxicity begins with support of airway, breathing, and circulation. Exogenous catecholamines should be avoided if possible due to the theoretical "sensitized" and irritable myocardium. In the case of ventricular dysrhythmias, direct current defibrillation and/or beta-adrenergic receptor antagonism should be used. New evidence demonstrates the addictive potential of VSM yet effective therapy remains uncertain. Further research is needed in developing methods for preventing, detecting, and treating the harmful effects of VSM.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23649409     DOI: 10.1007/s12016-013-8371-1

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  179 in total

1.  Inhaled drugs of abuse enhance serotonin-3 receptor function.

Authors:  Gregory F Lopreato; Rachel Phelan; Cecilia M Borghese; Michael J Beckstead; S John Mihic
Journal:  Drug Alcohol Depend       Date:  2003-05-01       Impact factor: 4.492

2.  Case files of the New York City poison control center: paradichlorobenzene-induced leukoencephalopathy.

Authors:  Stephanie H Hernandez; Sage W Wiener; Silas W Smith
Journal:  J Med Toxicol       Date:  2010-06

Review 3.  The last decade of solvent research in animal models of abuse: mechanistic and behavioral studies.

Authors:  Scott E Bowen; Jeffery C Batis; Nayeli Paez-Martinez; Silvia L Cruz
Journal:  Neurotoxicol Teratol       Date:  2006-09-20       Impact factor: 3.763

4.  Volatile substance misuse among youth in Israel: results of a national school survey.

Authors:  Yehuda Neumark; Rachel Bar-Hamburger
Journal:  Subst Use Misuse       Date:  2011       Impact factor: 2.164

5.  Saturday night blue--a case of near fatal poisoning from the abuse of amyl nitrite.

Authors:  T Stambach; K Haire; N Soni; J Booth
Journal:  J Accid Emerg Med       Date:  1997-09

Review 6.  Volatile substance abuse.

Authors:  G P Marelich
Journal:  Clin Rev Allergy Immunol       Date:  1997       Impact factor: 10.817

7.  Folinic acid protection against hematopoietic depression induced by nitrous oxide in rats.

Authors:  J H Lee; C H Sung; S H Moon; S N Kim; W H Chung
Journal:  Anesth Analg       Date:  1993-08       Impact factor: 5.108

Review 8.  The neurobehavioral toxicity of trichloroethylene.

Authors:  Z Annau
Journal:  Neurobehav Toxicol Teratol       Date:  1981

9.  Slow heart-slow brain: consequence of short-term occupational exposure to toluene in a young woman: what is the real mechanism?

Authors:  Cengizhan Türkoğlu; Farid Aliyev; Cengiz Celiker; Işil Uzunhasan; Cuneyt Kocaş
Journal:  Clin Cardiol       Date:  2010-02       Impact factor: 2.882

10.  Freon inhalational abuse presenting with ventricular fibrillation.

Authors:  W J Brady; E Stremski; L Eljaiek; T P Aufderheide
Journal:  Am J Emerg Med       Date:  1994-09       Impact factor: 2.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.